8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Mar 2, 2026·SEC
United Therapeutics Corporation(UTHR)Earnings, Financials & Key Ratios
UTHR•NASDAQ
$572.20
$24.97B mkt cap·20.5× P/E·Price updated May 6, 2026
AboutUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Show more
- Revenue$3.18B+10.6%
- EBITDA$1.58B+8.9%
- Net Income$1.33B+11.7%
- EPS (Diluted)27.86+13.1%
- Gross Margin87.92%-1.5%
- EBITDA Margin49.58%-1.6%
- Operating Margin46.89%-2.0%
- Net Margin41.94%+1.0%
- ROE19.71%+2.5%
- ROIC21.15%+7.8%
- Interest Coverage76.54+138.5%
UTHR Key Insights
United Therapeutics Corporation (UTHR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 21.0%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 32.7% free cash flow margin
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓Strong 5Y sales CAGR of 16.5%
- ✓Good 3Y average ROE of 19.1%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
UTHR Price & Volume
United Therapeutics Corporation (UTHR) stock price & volume — 10-year historical chart
Loading chart...
UTHR Growth Metrics
United Therapeutics Corporation (UTHR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.06%
5 Years16.5%
3 Years18.02%
TTM10.61%
Profit CAGR
10 Years7.43%
5 Years20.99%
3 Years22.43%
TTM11.68%
EPS CAGR
10 Years8.16%
5 Years19.28%
3 Years22.92%
TTM13.25%
Return on Capital
10 Years22.52%
5 Years18.59%
3 Years20.75%
Last Year21.41%
UTHR Recent Earnings
United Therapeutics Corporation (UTHR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 25, 2026EPS
$7.70
Est $7.13
+8.0%
Revenue
$790M
Est $813M
-2.8%
Q4 2025
Oct 29, 2025EPS
$7.16
Est $6.89
+3.9%
Revenue
$800M
Est $815M
-1.9%
Q3 2025
Jul 30, 2025EPS
$6.41
Est $7.29
-12.1%
Revenue
$799M
Est $802M
-0.4%
Q2 2025
Apr 30, 2025EPS
$6.63
Est $6.29
+5.4%
Revenue
$794M
Est $779M
+2.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $7.70vs $7.13+8.0% | $790Mvs $813M-2.8% |
| Q4 2025 | Oct 29, 2025 | $7.16vs $6.89+3.9% | $800Mvs $815M-1.9% |
| Q3 2025 | Jul 30, 2025 | $6.41vs $7.29-12.1% | $799Mvs $802M-0.4% |
| Q2 2025 | Apr 30, 2025 | $6.63vs $6.29+5.4% | $794Mvs $779M+2.0% |
Based on last 12 quarters of dataView full earnings history →
UTHR Peer Comparison
United Therapeutics Corporation (UTHR) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IDYA | 2.53B | 28.80 | -22.50 | 30.24% | -51.99% | -11.11% | 0.03 | |
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 PTGX | 6.21B | 99.28 | -48.43 | -100% | -21.17% | 0.93% | 0.02 | |
 INVA | 1.69B | 22.65 | 6.86 | 18.52% | 65.38% | 23.12% | 11.58% | |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 MNKD | 880.4M | 2.86 | 143 | 22.23% | 1.68% | 1.55% | ||
 LNTH | 5.59B | 85.82 | 25.17 | 0.5% | 15.15% | 20.58% | 6.34% | 0.00 |
Compare UTHR vs Peers
United Therapeutics Corporation (UTHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UTHR Income Statement
United Therapeutics Corporation (UTHR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.73B | 1.63B | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B |
| Revenue Growth % | 7.91% | -5.65% | -11% | 2.38% | 13.63% | 14.88% | 20.2% | 23.63% | 10.61% |
| Cost of Goods Sold | 105.7M | 198.7M | 117.6M | 108.1M | 122.5M | 146.7M | 257.5M | 309.7M | 384.4M |
| COGS % of Revenue | 6.13% | 12.21% | 8.12% | 7.29% | 7.27% | 7.58% | 11.06% | 10.76% | 12.08% |
| Gross Profit | 1.62B▲ 0% | 1.43B▼ 11.8% | 1.33B▼ 6.9% | 1.38B▲ 3.3% | 1.56B▲ 13.7% | 1.79B▲ 14.5% | 2.07B▲ 15.7% | 2.57B▲ 24.0% | 2.8B▲ 9.0% |
| Gross Margin % | 93.87% | 87.79% | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | 89.24% | 87.92% |
| Gross Profit Growth % | 6.13% | -11.76% | -6.85% | 3.31% | 13.66% | 14.5% | 15.67% | 24.04% | 8.98% |
| Operating Expenses | 594.7M | 623.7M | 1.52B | 781.6M | 1.01B | 809.9M | 885.1M | 1.19B | 1.31B |
| OpEx % of Revenue | 34.47% | 38.32% | 104.83% | 52.69% | 59.75% | 41.83% | 38.03% | 41.38% | 41.03% |
| Selling, General & Admin | 330.1M | 265.8M | 336.2M | 423.9M | 467M | 487M | 477.1M | 638.6M | 755.8M |
| SG&A % of Revenue | 19.13% | 16.33% | 23.21% | 28.58% | 27.71% | 25.15% | 20.5% | 22.19% | 23.75% |
| Research & Development | 264.6M | 357.9M | 1.18B | 357.7M | 540.1M | 322.9M | 408M | 481M | 550M |
| R&D % of Revenue | 15.34% | 21.99% | 81.63% | 24.12% | 32.04% | 16.68% | 17.53% | 16.72% | 17.28% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71.1M | 0 |
| Operating Income | 814.9M▲ 0% | 805.4M▼ 1.2% | -187.6M▼ 123.3% | 593.6M▲ 416.4% | 555.9M▼ 6.4% | 979.7M▲ 76.2% | 1.18B▲ 20.9% | 1.38B▲ 16.2% | 1.49B▲ 8.4% |
| Operating Margin % | 47.23% | 49.48% | -12.95% | 40.02% | 32.98% | 50.6% | 50.91% | 47.86% | 46.89% |
| Operating Income Growth % | -23.25% | -1.17% | -123.29% | 416.42% | -6.35% | 76.24% | 20.95% | 16.21% | 8.39% |
| EBITDA | 845.9M | 841.3M | -141.7M | 643.5M | 605.8M | 1.03B | 1.24B | 1.45B | 1.58B |
| EBITDA Margin % | 49.03% | 51.68% | -9.78% | 43.38% | 35.94% | 53.25% | 53.19% | 50.38% | 49.58% |
| EBITDA Growth % | -22.63% | -0.54% | -116.84% | 554.13% | -5.86% | 70.19% | 20.09% | 17.07% | 8.87% |
| D&A (Non-Cash Add-back) | 31M | 35.9M | 45.9M | 49.9M | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| EBIT | 1.02B | 802.5M | -120.8M | 596.4M | 686.9M | 989M | 1.33B | 1.58B | 1.73B |
| Net Interest Income | 1.9M | 14.7M | 0 | 5.1M | -1.9M | 12.8M | 103.4M | 156.2M | 172.5M |
| Interest Income | 10.9M | 28.6M | 44.2M | 28.6M | 16.7M | 45.2M | 162.7M | 199.1M | 192M |
| Interest Expense | 9M | 13.9M | 44.2M | 23.5M | 18.6M | 32.4M | 59.3M | 42.9M | 19.5M |
| Other Income/Expense | -45.4M | -46.5M | 22.6M | 45.3M | 38M | -29.1M | 89.4M | 162M | 221.4M |
| Pretax Income | 769.5M▲ 0% | 758.9M▼ 1.4% | -165M▼ 121.7% | 638.9M▲ 487.2% | 593.9M▼ 7.0% | 950.6M▲ 60.1% | 1.27B▲ 34.1% | 1.54B▲ 20.8% | 1.71B▲ 11.4% |
| Pretax Margin % | 44.6% | 46.62% | -11.39% | 43.07% | 35.24% | 49.09% | 54.75% | 53.49% | 53.85% |
| Income Tax | 351.6M | 169.7M | -60.5M | 124.1M | 118.1M | 223.3M | 289.5M | 343.9M | 379.2M |
| Effective Tax Rate % | 45.69% | 22.36% | 36.67% | 19.42% | 19.89% | 23.49% | 22.72% | 22.35% | 22.12% |
| Net Income | 417.9M▲ 0% | 589.2M▲ 41.0% | -104.5M▼ 117.7% | 514.8M▲ 592.6% | 475.8M▼ 7.6% | 727.3M▲ 52.9% | 984.8M▲ 35.4% | 1.2B▲ 21.4% | 1.33B▲ 11.7% |
| Net Margin % | 24.22% | 36.2% | -7.21% | 34.71% | 28.23% | 37.56% | 42.31% | 41.53% | 41.94% |
| Net Income Growth % | -41.45% | 40.99% | -117.74% | 592.63% | -7.58% | 52.86% | 35.4% | 21.35% | 11.68% |
| Net Income (Continuing) | 417.9M | 589.2M | -104.5M | 514.8M | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 9.31▲ 0% | 13.39▲ 43.8% | -2.39▼ 117.8% | 11.54▲ 582.8% | 10.06▼ 12.8% | 15.00▲ 49.1% | 19.81▲ 32.1% | 24.64▲ 24.4% | 27.86▲ 13.1% |
| EPS Growth % | -38.95% | 43.82% | -117.85% | 582.85% | -12.83% | 49.11% | 32.07% | 24.38% | 13.07% |
| EPS (Basic) | 9.50 | 13.54 | -2.39 | 11.65 | 10.60 | 15.98 | 21.04 | 26.44 | 30.13 |
| Diluted Shares Outstanding | 44.9M | 44M | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 48.5M | 47.9M |
| Basic Shares Outstanding | 44M | 43.5M | 43.8M | 44.2M | 44.9M | 45.5M | 46.8M | 45.2M | 44.3M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
UTHR Balance Sheet
United Therapeutics Corporation (UTHR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.45B | 1.77B | 1.86B | 2.17B | 2.32B | 3.38B | 3.55B | 3.87B | 3.7B |
| Cash & Short-Term Investments | 927.4M | 1.42B | 1.49B | 1.83B | 1.93B | 2.84B | 2.99B | 3.27B | 1.56B |
| Cash Only | 705.1M | 669.2M | 738.4M | 738.7M | 894.8M | 961.2M | 1.21B | 1.7B | 1.56B |
| Short-Term Investments | 222.3M | 746.7M | 747.5M | 1.1B | 1.04B | 1.88B | 1.79B | 1.57B | 0 |
| Accounts Receivable | 297.1M | 175.7M | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 279.3M | 350.2M |
| Days Sales Outstanding | 62.85 | 39.4 | 38.14 | 38.73 | 43.03 | 41.55 | 43.74 | 35.43 | 40.16 |
| Inventory | 107.9M | 101M | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 157.9M | 183.1M |
| Days Inventory Outstanding | 372.6 | 185.53 | 289.89 | 292.07 | 279.49 | 253.78 | 158.47 | 186.09 | 173.86 |
| Other Current Assets | 115.5M | 75.4M | -633.7M | 88.3M | 100.4M | 219.2M | 166.2M | 169.7M | 1.61B |
| Total Non-Current Assets | 1.43B | 1.63B | 2.05B | 2.45B | 2.85B | 2.66B | 3.62B | 3.49B | 4.18B |
| Property, Plant & Equipment | 545.7M | 699.7M | 738.5M | 731.6M | 780.9M | 861.5M | 1.05B | 1.22B | 1.73B |
| Fixed Asset Turnover | 3.16x | 2.33x | 1.96x | 2.03x | 2.16x | 2.25x | 2.23x | 2.35x | 1.84x |
| Goodwill | 13.7M | 31.5M | 28M | 28M | 28M | 28M | 33.7M | 32.3M | 0 |
| Intangible Assets | 31.9M | 139.3M | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 79.6M | 116.5M |
| Long-Term Investments | 502.7M | 442.6M | 767.5M | 1.15B | 1.65B | 1.32B | 1.91B | 1.48B | 1.78B |
| Other Non-Current Assets | 224.1M | 224.2M | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 222.1M | 196.9M |
| Total Assets | 2.88B▲ 0% | 3.4B▲ 18.1% | 3.91B▲ 15.1% | 4.62B▲ 17.9% | 5.17B▲ 12.0% | 6.04B▲ 16.9% | 7.17B▲ 18.6% | 7.36B▲ 2.7% | 7.88B▲ 7.0% |
| Asset Turnover | 0.60x | 0.48x | 0.37x | 0.32x | 0.33x | 0.32x | 0.32x | 0.39x | 0.40x |
| Asset Growth % | 23.81% | 18.11% | 15.07% | 17.93% | 12.01% | 16.94% | 18.57% | 2.75% | 7.01% |
| Total Current Liabilities | 444.7M | 276.6M | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 738.1M | 560.6M |
| Accounts Payable | 8.4M | 23.1M | 9.9M | 4.1M | 3.8M | 4.1M | 5.6M | 6M | 0 |
| Days Payables Outstanding | 29.01 | 42.43 | 30.73 | 13.84 | 11.32 | 10.2 | 7.94 | 7.07 | - |
| Short-Term Debt | 0 | 0 | 250M | 0 | 0 | 0 | 400M | 300M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 163.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 401.7M | 215.6M | -141.4M | 20.4M | 248M | 13M | 40.5M | 432.1M | 560.6M |
| Current Ratio | 3.26x | 6.39x | 4.03x | 6.70x | 7.61x | 9.85x | 4.41x | 5.25x | 6.60x |
| Quick Ratio | 3.01x | 6.03x | 3.83x | 6.44x | 7.30x | 9.55x | 4.28x | 5.03x | 6.28x |
| Cash Conversion Cycle | 406.44 | 182.49 | 297.31 | 316.96 | 311.19 | 285.13 | 194.27 | 214.45 | - |
| Total Non-Current Liabilities | 313.7M | 316.6M | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 181.9M | 223.2M |
| Long-Term Debt | 250M | 250M | 600M | 800M | 800M | 800M | 300M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 63.7M | 66.6M | 70M | 96.5M | 104.8M | 104.6M | 77.8M | 181.9M | 223.2M |
| Total Liabilities | 777.6M | 612.4M | 1.13B | 1.22B | 1.21B | 1.25B | 1.18B | 920M | 783.8M |
| Total Debt | 250M | 250M | 850M | 800M | 800M | 800M | 700M | 300M | 0 |
| Net Debt | -455.1M | -419.2M | 111.6M | 61.3M | -94.8M | -161.2M | -507.7M | -1.4B | -1.56B |
| Debt / Equity | 0.12x | 0.09x | 0.31x | 0.24x | 0.20x | 0.17x | 0.12x | 0.05x | - |
| Debt / EBITDA | 0.30x | 0.30x | - | 1.24x | 1.32x | 0.78x | 0.57x | 0.21x | - |
| Net Debt / EBITDA | -0.54x | -0.50x | - | 0.10x | -0.16x | -0.16x | -0.41x | -0.96x | -0.99x |
| Interest Coverage | 90.54x | 57.94x | -4.24x | 25.26x | 29.89x | 30.24x | 19.98x | 32.10x | 76.54x |
| Total Equity | 2.1B▲ 0% | 2.79B▲ 32.7% | 2.78B▼ 0.3% | 3.4B▲ 22.1% | 3.96B▲ 16.6% | 4.8B▲ 21.2% | 5.98B▲ 24.8% | 6.44B▲ 7.7% | 7.1B▲ 10.1% |
| Equity Growth % | 12.87% | 32.68% | -0.29% | 22.11% | 16.6% | 21.16% | 24.77% | 7.67% | 10.12% |
| Book Value per Share | 46.81 | 63.38 | 63.48 | 76.13 | 83.70 | 98.90 | 120.42 | 132.87 | 148.15 |
| Total Shareholders' Equity | 2.1B | 2.79B | 2.78B | 3.4B | 3.96B | 4.8B | 5.98B | 6.44B | 7.1B |
| Common Stock | 700K | 700K | 700K | 700K | 700K | 700K | 700K | 800K | 800K |
| Retained Earnings | 2.85B | 3.43B | 3.33B | 3.84B | 4.32B | 5.04B | 6.03B | 7.22B | 8.56B |
| Treasury Stock | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -3.47B | -4.26B |
| Accumulated OCI | -19.6M | -7.9M | -14.2M | -14.2M | -23M | -55.5M | -12.8M | -3.4M | 900K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UTHR Cash Flow Statement
United Therapeutics Corporation (UTHR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 474.2M | 778.4M | -206.6M | 755.7M | 598.2M | 802.5M | 978M | 1.33B | 1.56B |
| Operating CF Margin % | 27.49% | 47.82% | -14.26% | 50.95% | 35.49% | 41.45% | 42.02% | 46.12% | 49.05% |
| Operating CF Growth % | -26.32% | 64.15% | -126.54% | 465.78% | -20.84% | 34.15% | 21.87% | 35.7% | 17.64% |
| Net Income | 417.9M | 589.2M | -104.5M | 514.8M | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Depreciation & Amortization | 31M | 35.9M | 45.9M | 49.9M | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| Stock-Based Compensation | 73.5M | -26.4M | 45.4M | 163.8M | 138.5M | 106.8M | 39.1M | 144M | 147.7M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97.7M |
| Other Non-Cash Items | 30.2M | 55.3M | -15.1M | -35.9M | 108.2M | 58.3M | -1.3M | -24.3M | 2M |
| Working Capital Changes | -78.4M | 124.4M | -178.3M | 63.1M | -174.2M | -141.2M | -97.8M | -60.2M | -106.4M |
| Change in Receivables | -82.7M | 121.4M | 24.4M | -6M | -41.3M | -21.7M | -58.5M | -400K | -70.9M |
| Change in Inventory | -500K | 9.3M | 12.9M | 10.3M | -7.5M | -13.4M | -13.6M | -46.9M | -52.6M |
| Change in Payables | 66.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97.9M |
| Cash from Investing | -835.6M | -820.6M | -335.4M | -738.5M | -486.9M | -811.5M | -719.6M | 417.2M | -551.3M |
| Capital Expenditures | -86.3M | -184.4M | -83.7M | -59.3M | -120.8M | -138.8M | -230.4M | -246.5M | -520.5M |
| CapEx % of Revenue | 5% | 11.33% | 5.78% | 4% | 7.17% | 7.17% | 9.9% | 8.57% | 16.35% |
| Acquisitions | -60.3M | -129.1M | -20.5M | 0 | 0 | -1.5M | -89.2M | -30.5M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 8.3M | -46M | 0 | 2.4M | 0 | 3.5M | -23M | -28.5M | 1.85B |
| Cash from Financing | 43.3M | 6.3M | 611.2M | -16.9M | 44.8M | 75.4M | -11.9M | -1.25B | -1.15B |
| Debt Issued (Net) | 250M | 0 | 600M | -50M | 0 | 0 | -100M | -400M | -300M |
| Equity Issued (Net) | -1000K | 0 | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -250M | 0 | -2.1M | -3.7M | -10.8M | -11.4M | -13.8M | -1.01B | -1B |
| Other Financing | 43.3M | 6.3M | 13.3M | 36.8M | 55.6M | 86.8M | 101.9M | 157.4M | -33.1M |
| Net Change in Cash | -317.9M▲ 0% | -35.9M▲ 88.7% | 69.2M▲ 292.8% | 300K▼ 99.6% | 156.1M▲ 51933.3% | 66.4M▼ 57.5% | 246.5M▲ 271.2% | 489.5M▲ 98.6% | -140.1M▼ 128.6% |
| Free Cash Flow | 387.9M▲ 0% | 594M▲ 53.1% | -290.3M▼ 148.9% | 696.4M▲ 339.9% | 477.4M▼ 31.4% | 663.7M▲ 39.0% | 747.6M▲ 12.6% | 1.08B▲ 44.5% | 1.04B▼ 3.7% |
| FCF Margin % | 22.48% | 36.49% | -20.04% | 46.95% | 28.32% | 34.28% | 32.12% | 37.55% | 32.7% |
| FCF Growth % | -35.39% | 53.13% | -148.87% | 339.89% | -31.45% | 39.02% | 12.64% | 44.54% | -3.69% |
| FCF per Share | 8.64 | 13.50 | -6.63 | 15.61 | 10.09 | 13.68 | 15.04 | 22.28 | 21.73 |
| FCF Conversion (FCF/Net Income) | 1.13x | 1.32x | 1.98x | 1.47x | 1.26x | 1.10x | 0.99x | 1.11x | 1.17x |
| Interest Paid | 7.5M | 9.4M | 41M | 20.7M | 16.2M | 29.1M | 56M | 40.2M | 13.5M |
| Taxes Paid | 346.9M | 102.7M | 120.2M | 92.8M | 153.3M | 275.7M | 332.5M | 400.6M | 313.3M |
UTHR Key Ratios
United Therapeutics Corporation (UTHR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 41.23% | 21.08% | 24.1% | -3.75% | 16.67% | 12.94% | 16.61% | 18.27% | 19.23% | 19.71% |
| Return on Invested Capital (ROIC) | 98.77% | 49.17% | 30.08% | -5.35% | 14.03% | 11.39% | 17.29% | 17.58% | 19.63% | 21.15% |
| Gross Margin | 95.45% | 93.87% | 87.79% | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | 89.24% | 87.92% |
| Net Margin | 44.64% | 24.22% | 36.2% | -7.21% | 34.71% | 28.23% | 37.56% | 42.31% | 41.53% | 41.94% |
| Debt / Equity | - | 0.12x | 0.09x | 0.31x | 0.24x | 0.20x | 0.17x | 0.12x | 0.05x | - |
| Interest Coverage | 272.23x | 90.54x | 57.94x | -4.24x | 25.26x | 29.89x | 30.24x | 19.98x | 32.10x | 76.54x |
| FCF Conversion | 0.90x | 1.13x | 1.32x | 1.98x | 1.47x | 1.26x | 1.10x | 0.99x | 1.11x | 1.17x |
| Revenue Growth | 9.08% | 7.91% | -5.65% | -11% | 2.38% | 13.63% | 14.88% | 20.2% | 23.63% | 10.61% |
UTHR SEC Filings & Documents
United Therapeutics Corporation (UTHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
UTHR Frequently Asked Questions
United Therapeutics Corporation (UTHR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
United Therapeutics Corporation (UTHR) reported $3.18B in revenue for fiscal year 2025. This represents a 3182600% increase from $0.1M in 1998.
United Therapeutics Corporation (UTHR) grew revenue by 10.6% over the past year. This is steady growth.
Yes, United Therapeutics Corporation (UTHR) is profitable, generating $1.33B in net income for fiscal year 2025 (41.9% net margin).
Dividend & Returns
United Therapeutics Corporation (UTHR) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.
United Therapeutics Corporation (UTHR) generated $1.04B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More UTHR
United Therapeutics Corporation (UTHR) financial analysis — history, returns, DCA and operating performance tools
Full UTHR Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates